We demonstrate that, by harnessing a natural mechanism of gene silencing (RNAi), synthetic siRNA therapeutics can selectively silence JAK1 to inhibit IFN-γ-JAK1/2-STAT1-CXCL9/10/11 signaling and mitigate vitiligo pathogenesis. The gene discussed is JAK1; the disease is vitiligo.